Elevance Health, Inc. (ELV)
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.
Why Is Elevance Health (ELV) Up 7.3% Since Last Earnings Report?
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
Elevance Health: Healthcare Services Segment Is Gaining Traction
Elevance Health's health insurance segment is well diversified, with a meaningful exposure to commercial services-only memberships and Medicaid. ELV has been doing a great job handling the current environment of rising medical costs. The Healthcare Services segment is starting to meaningfully grow external revenue.
BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations
Wednesday, Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
Elevance Health: Buy A Dividend Growth Machine
Elevance Health, Inc. has shown remarkable dividend growth in the past decade, exceeding revenue and EPS expectations for the first quarter. Elevance's balance sheet remains A-rated, and shares of the stock could be undervalued by 14%. The company is positioned to generate over 30% cumulative total returns through 2026, making it a high-quality investment option.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
Elevance Health, Inc. (ELV) Q2 2024 Earnings Call Transcript
Elevance Health, Inc. (NYSE:ELV ) Q2 2024 Earnings Call Transcript July 17, 2024 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO Mark Kaye - CFO Felicia Norwood - President, Government Health Benefits Pete Haytaian - President, Carelon Morgan Kendrick - President, Commercial Health Benefits Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Lance Wilkes - Bernstein Kevin Fischbeck - Bank of America Josh Raskin - Nephron Research Lisa Gill - JPMorgan Justin Lake - Wolfe Research Erin Wright - Morgan Stanley Michael Ha - Baird Andrew Mok - Barclays Ryan Langston - Cowen Stephen Baxter - Wells Fargo Scott Fidel - Stephens Sarah James - Cantor Fitzgerald George Hill - Deutsche Bank Whit Mayo - Leerink Partners Dave Windley - Jefferies Ann Hynes - Mizuho Securities Ben Hendrix - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Second Quarter Earnings Conference Call.
Elevance Stock Slides Despite Earnings Beat as Medicaid Membership Declines
Elevance Health (ELV) topped analyst expectations with its second-quarter results, but shares of the health insurance provider fell in intraday trading Wednesday amid declining Medicaid membership.
Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health Beat Street Estimates On Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Inc. ELV reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion.
